Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Macro H2A nonhistone cofactors posttranslational
- Product Overview:
MacroH2A proteins are variant histones that are enriched on inactivated X chromosomes and have roles in the maintenance of nuclear organization and heterochromatin architecture.{57292,57293,58069} MacroH2A1 is encoded by MACROH2A1 and can exist as two isoforms, macroH2A1.1 and macroH2A1.2, produced by alternative splicing, and macroH2A2 is encoded by MACROH2A2.{57293} MacroH2As are comprised of a histone fold, which is approximately 65% identical to canonical histone H2A, a basic linker, and a C-terminal non-histone macrodomain, which is unique to macroH2As and protrudes from the nucleosome core to recruit various co-factors.{58069,57292,57293} The non-histone region of macroH2A2 is 68% identical to that of macroH2A1.2, whereas the macrodomain of macroH2A1.1 is unique in that it can bind to ADP-ribose and ADP-ribosylated proteins.{57293,58069} Low levels of macroH2A1.1 are associated with poor prognosis in patients with lung or colon cancer, and loss of macroH2A2 expression is associated with earlier recurrence of lesions in patients with anal intraepithelial neoplasia (AIN).{58069,57294} MacroH2A1.2 expression is increased in highly proliferative cancer cell lines, but it can act as a tumor suppressor in melanoma and bladder cancer, indicating that its role in cancer is context-dependent. Cayman’s Histone MacroH2A1/MacroH2A2 (C-Term) Monoclonal Antibody can be used for ELISA, immunocytochemistry (ICC), multiplex-based assay, and Western blot (WB) applications. The antibody recognizes the C-terminus of macroH2A1 and macroH2A2 independent of post-translational modifications (PTMs).
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.